#China #Hangzhou #CXG87 #Asthma Treatment #Chance Pharmaceuticals

Chance Pharma's CXG87 Receives NMPA Acceptance

Hangzhou, China – In a major development for respiratory therapy, Chance Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has accepted their New Drug Application (NDA) for CXG87, an investigational inhalation drug designed to treat asthma. This marks a significant milestone for Chance Pharma, making it the first NDA submitted by the company.

About CXG87
CXG87 is an innovative formulation of a combination of budesonide and formoterol fumarate, specifically engineered for inhalation via a hard capsule. As a Class 2.2 innovative drug, it offers a new approach in managing respiratory diseases like asthma. The initiation of this NDA acceptance signifies an important step toward the commercialization of advanced treatment options for patients afflicted by respiratory conditions.

Clinical Trials and Findings
The journey of CXG87 is supported by promising results from extensive clinical trials. Over 42 days of Phase III trials, this new medication demonstrated non-inferiority when compared to the well-known Symbicort® Turbuhaler®. Primary outcomes indicated that patients receiving CXG87 showed notable improvement in lung function, alongside a reduction in asthma symptoms and a decrease in the frequency of exacerbations. Importantly, its safety profile was found to be comparable to its active counterpart. The results are particularly encouraging for patients with lower inspiratory abilities, as CXG87 is designed to accommodate a broader range of inspiratory flow rates, suggesting it could effectively serve a high number of asthma sufferers.

Dr. Donghao Chen, the Founder and CEO of Chance Pharma, expressed, “The acceptance of our NDA by NMPA for CXG87 is a testament to our scientific expertise and unwavering commitment to delivering innovative inhalation therapies. This product significantly mitigates the limitations of traditional inhalers, enabling more patients to achieve effective disease management.”

Significance for Asthma Patients
Asthma represents one of the most prevalent chronic respiratory conditions globally, impacting around 300 million individuals, yet only about half of these cases are effectively controlled. In China alone, reports indicate that nearly 50 million adults suffer from asthma, with a mere 28.5% achieving satisfactory control of their symptoms. This scenario underscores the pressing need for new treatment options. The positive preliminary results from CXG87 are expected not only to enhance patient outcomes but also to contribute to the overall management of asthma in the crowded pharmaceutical landscape.

As Dr. Lan Chen, the Head of Research and Development at Chance Pharma, stated, “Our endeavor has been to refine and improve a well-established treatment through CXG87. We are optimistic that the extensive data from our trials will eventually facilitate better management for asthma, especially among patients who have struggled with conventional delivery methods.”

Aiming for Effective Asthma Management
The Guidelines for the Prevention and Treatment of Bronchial Asthma highlight the treatment approach for managing asthma through inhaled corticosteroid/formoterol combinations. However, many factors hinder effective medication delivery, notably the patients’ individual characteristics and inhalation techniques. CXG87 stands out by addressing these critical factors, providing a viable solution to a significant healthcare challenge.

About Chance Pharmaceuticals
Founded in 2015, Chance Pharmaceuticals has dedicated itself to pioneering inhalation therapies that change lives. Utilizing advanced technology platforms, the company has developed a robust product pipeline aimed at enhancing the clinical efficacy of therapies delivered through inhalation. The state-of-the-art manufacturing facility complies with international standards, enabling seamless transitions from research to product development.

As the pharmaceutical landscape continues to evolve, Chance Pharmaceuticals remains steadfast in its mission of “harnessing respiratory delivery technology to deliver clinical value.” This dedication to innovation promises not only to improve the management of asthma but also to elevate the quality of life for patients worldwide. For further information on Chance Pharmaceuticals and its initiatives, visit www.chancepharmaceuticals.com.